Literature DB >> 8735183

The hypertensive Ren-2 transgenic rat TGR (mREN2)27 in hypertension research. Characteristics and functional aspects.

M Langheinrich1, M A Lee, M Böhm, Y M Pinto, D Ganten, M Paul.   

Abstract

Primary human hypertension is a polygenic disorder. It is the prevalent cause of cardiovascular disease leading to cardiac failure, stroke, chronic renal failure and, ultimately to death. Several genes are involved in cardiovascular control mechanisms and their genetics are complex. Experimental models which are well defined are needed to clarify the role of individual genes. The generation of the hypertensive transgenic rat line TGR (mREN2)27 bearing the murine Ren-2 gene cloned from the DBA/2J mouse strain provides a monogenic model of hypertension in which the genetic basis (the additional renin gene) is known. These rats develop severe hypertension, which reaches 200 mm Hg and higher at 8 weeks of age in the heterozygous animal. Homozygous rats develop even higher blood pressures than heterozygous animals, which is paralleled by a higher mortality rate in homozygous rats. Animals develop pathomorphologic alterations which are characteristic for systemic hypertension. The transgenic rats are characterized by unchanged or even suppressed concentrations of active renin, angiotensin I (ANG I), ANG II, and angiotensinogen compared to transgene-negative littermates. In contrast, plasma levels of inactive renin (prorenin) are much higher in TGR (mREN)27 rats than in control animals. In the kidneys, renin is suppressed, probably mediated through negative feedback inhibition, in other tissues, especially in the adrenal gland, murine Ren-2 mRNA is expressed at very high levels. The cascade of pathophysiologic events which finally lead to hypertension is not fully understood in this rat model. Treatment with ACE inhibitors or angiotensin II receptor antagonists such as losartan is extremely efficient, which could mean that hypertension in this model is mediated through ANG II. Since the the renin-angiotensin system (RAS) in the kidneys is suppressed, other ANG II generating sites must be considered. This favors the concept of extrarenal RASs in this model.

Entities:  

Mesh:

Year:  1996        PMID: 8735183     DOI: 10.1016/0895-7061(95)00400-9

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  16 in total

1.  Role of phosphatidylinositol 3-kinase in angiotensin II regulation of norepinephrine neuromodulation in brain neurons of the spontaneously hypertensive rat.

Authors:  H Yang; M K Raizada
Journal:  J Neurosci       Date:  1999-04-01       Impact factor: 6.167

2.  Alamandine enhances cardiomyocyte contractility in hypertensive rats through a nitric oxide-dependent activation of CaMKII.

Authors:  Itamar Couto Guedes Jesus; Thássio Ricardo Ribeiro Mesquita; André Luís Lima Monteiro; Amanda Borges Parreira; Anderson Kenedy Santos; Elizeu Lucas Xavier Coelho; Mário Morais Silva; Lucas A C Souza; Maria José Campagnole-Santos; Robson Souza Santos; Silvia Guatimosim
Journal:  Am J Physiol Cell Physiol       Date:  2020-01-08       Impact factor: 4.249

Review 3.  New insights into the renin-angiotensin system and hypertensive renal disease.

Authors:  A B Fogo
Journal:  Curr Hypertens Rep       Date:  1999 Apr-May       Impact factor: 5.369

4.  Combination of direct renin inhibition with angiotensin type 1 receptor blockade improves aldosterone but does not improve kidney injury in the transgenic Ren2 rat.

Authors:  Adam Whaley-Connell; Javad Habibi; Ravi Nistala; Melvin R Hayden; Lakshmi Pulakat; Catherine Sinak; Bonnie Locher; Carlos M Ferrario; James R Sowers
Journal:  Regul Pept       Date:  2012-03-29

5.  The functional role of PI3K in maintenance of blood pressure and baroreflex suppression in (mRen2)27 and mRen2.Lewis rat.

Authors:  Exazevia M Logan; Azeez A Aileru; Hossam A Shaltout; David B Averill; Debra I Diz
Journal:  J Cardiovasc Pharmacol       Date:  2011-10       Impact factor: 3.105

6.  Calcineurin independent development of myocardial hypertrophy in transgenic rats overexpressing the mouse renin gene, TGR(mREN2)27.

Authors:  H Diedrichs; C Mei; K F Frank; B Boelck; R H G Schwinger
Journal:  J Mol Med (Berl)       Date:  2004-08-20       Impact factor: 4.599

7.  Angiotensin-converting enzyme is a modifier of hypertensive end organ damage.

Authors:  Xiaojun Liu; Christopher O C Bellamy; Matthew A Bailey; Linda J Mullins; Donald R Dunbar; Christopher J Kenyon; Gillian Brooker; Surasak Kantachuvesiri; Klio Maratou; Ali Ashek; Allan F Clark; Stewart Fleming; John J Mullins
Journal:  J Biol Chem       Date:  2009-03-23       Impact factor: 5.157

8.  Bmal1 in Perivascular Adipose Tissue Regulates Resting-Phase Blood Pressure Through Transcriptional Regulation of Angiotensinogen.

Authors:  Lin Chang; Wenhao Xiong; Xiangjie Zhao; Yanbo Fan; Yanhong Guo; Minerva Garcia-Barrio; Jifeng Zhang; Zhisheng Jiang; Jiandie D Lin; Y Eugene Chen
Journal:  Circulation       Date:  2018-01-25       Impact factor: 29.690

Review 9.  The sweeter side of ACE2: physiological evidence for a role in diabetes.

Authors:  Sharell M Bindom; Eric Lazartigues
Journal:  Mol Cell Endocrinol       Date:  2008-10-01       Impact factor: 4.102

10.  Transgenic mice overexpressing Renin exhibit glucose intolerance and diet-genotype interactions.

Authors:  Sarah J Fletcher; Nishan S Kalupahana; Morvarid Soltani-Bejnood; Jung Han Kim; Arnold M Saxton; David H Wasserman; Bart De Taeye; Brynn H Voy; Annie Quignard-Boulange; Naima Moustaid-Moussa
Journal:  Front Endocrinol (Lausanne)       Date:  2013-01-07       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.